Engineered Bifidobacterium oral vaccine shows safety and immune response in Phase I cancer trial

A new oral vaccine platform that employs genetically engineered Bifidobacterium has entered early human testing, showing promise for boosting anti‑tumor immune responses. In a Phase I exploratory study, participants received the vaccine orally and reported no serious adverse events, indicating that the treatment was well tolerated. Immune assays revealed measurable activation of tumor‑specific T cells, and preliminary clinical observations suggested a reduction in tumor burden in a subset of patients.

The study also identified several potential biomarkers that could predict which patients are most likely to benefit from the vaccine. Levels of certain cytokines and immune cell subsets correlated with stronger vaccine‑induced responses, offering a roadmap for future trials to stratify patients and personalize therapy. These findings provide a foundation for larger, controlled studies aimed at confirming efficacy and refining patient selection criteria.